Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 3

Conditions

Papillomavirus Infections 4Uterine Cervical Neoplasms 3Hepatitis B 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Engerix-B × Clear all
NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

GlaxoSmithKline

Phase 3 Completed
152 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00534638 2019-11-15

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

GlaxoSmithKline

Phase 4 Completed
34,412 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
744 enrolled 27 charts
Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01082861 2010-03-19

TANGO

National Institute for Public Health and the Environment (RIVM)

Phase 4 Terminated

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡